ArriVent BioPharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AVBP | COGT | AGMB | SMMT | SNDX | ORIC | |
|---|---|---|---|---|---|---|
| Market cap | 665.16M | 5.46B | 337.35M | 12.90B | 940.80M | 968.12M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.6 | -26.3 | -3.4 | -13.8 | -14.4 | -5.5 |
| Price/book | 1.8 | 11.6 | 2.7 | 19.0 | -54.7 | 2.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −28.97% | +115.40% | −53.24% | −12.56% | −5.36% | −22.54% |
| Today | +3.61% | +1.38% | 0.00% | +2.34% | −26.87% | −2.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AVBP news ›Assembly Biosciences (NASDAQ:ASMB) Price Target Cut to $48.00 by Analysts at UBS Group
Posted by Danessa Lincoln on Nov 3rd, 2026 Assembly Biosciences (NASDAQ:ASMB – Get Free Report) had its target price dropped by analysts at UBS Group from $52.00 to $48.00 in a note issued to investors on Tuesday, Benzinga reports. The…
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 6.8% – Here’s Why
Posted by Kim Johansen on Nov 2nd, 2026 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report) traded down 6.8% during mid-day trading on Monday. The stock traded as low as $13.85 and last traded at $13.8650. Approximately…
Denali Therapeutics price target raised to $34 from $31 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $31 and keeps an Outperform rating on the shares. The firm update... Denali Therapeutics price target raised to $34 from $31 at Baird Baird raised the firm’s…
Denali Therapeutics price target raised to $35 from $30 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $30 and keeps a Buy rating on the share... Denali Therapeutics price target raised to $35 from $30 at B. Riley B. Riley analyst Mayank…
Altimmune price target lowered to $17 from $18 at Evercore ISI
Evercore ISI analyst Michael DiFiore lowered the firm’s price target on Altimmune (ALT) to $17 from $18 and keeps an Outperform rating on the sh... Altimmune price target lowered to $17 from $18 at Evercore ISI Evercore ISI analyst Michael…
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9
Candel Therapeutics has an average rating of buy and mean price target of $20.88, according to analysts polled by FactSet. ... Biotechnology & Medical Research BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 Published on…
Newtown Square Biotech ArriVent’s Stock Drops 47 Percent After Cancer Drug Trial Falls Short
I wanted to see what I could find as just a regular customer at an ALDI store about where they are sourcing their beef from. Here is what you can expect to find or in this case, not find about where their beef comes from. Lidl shoppers…
Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug
Actinium Pharmaceuticals, Inc. amended its Investigational New Drug application to add an additional manufacturer. The additional manufacturer will supply studies conducted under the Company's... amended its Investigational New Drug (IND)…
ORBIMED ADVISORS LLC Trims ArriVent BioPharma Inc (AVBP) Stake by 5.00%
GuruFocus ORBIMED ADVISORS LLC Trims ArriVent BioPharma Inc (AVBP) Stake by 5.00% A Strategic Portfolio Adjustment by a Healthcare Investment Giant On 2026-10-06, ORBIMED ADVISORS LLC (Trades, Portfolio) executed a transaction
ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors GlobeNewswire 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (âArriventâ or the âCompanyâ)…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com11
- marketscreener.com3
- prnewswire.com3
- themarketsdaily.com3
- globenewswire.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 32 articles, not a forecast.